These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24392981)

  • 21. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES.
    Lipkovich I; Dmitrienko A
    J Biopharm Stat; 2014; 24(1):130-53. PubMed ID: 24392982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating treatment effects in clinical crossover trials.
    Grieve A; Senn S
    J Biopharm Stat; 1998 May; 8(2):191-233; discussion 235-47. PubMed ID: 9598420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.
    Lipkovich I; Dmitrienko A; Denne J; Enas G
    Stat Med; 2011 Sep; 30(21):2601-21. PubMed ID: 21786278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian estimate of the concordance correlation coefficient with skewed data.
    Feng D; Baumgartner R; Svetnik V
    Pharm Stat; 2015; 14(4):350-8. PubMed ID: 26033433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian sample size determination for a clinical trial with correlated continuous and binary outcomes.
    Stamey JD; Natanegara F; Seaman JW
    J Biopharm Stat; 2013; 23(4):790-803. PubMed ID: 23786161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians.
    Kalil AC; Sun J
    Crit Care Med; 2014 Oct; 42(10):2267-77. PubMed ID: 25226118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A predictive Bayesian approach to the design and analysis of bridging studies.
    Gould AL; Jin T; Zhang LX; Wang WW
    J Biopharm Stat; 2012 Sep; 22(5):916-34. PubMed ID: 22946940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.
    Schnell PM; Müller P; Tang Q; Carlin BP
    Clin Trials; 2018 Feb; 15(1):75-86. PubMed ID: 29035083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian analysis of hierarchical pattern-mixture models for clinical trials data with attrition and comparisons to commonly used ad-hoc and model-based approaches.
    Demirtas H
    J Biopharm Stat; 2005; 15(3):383-402. PubMed ID: 15920887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Borrowing information across subgroups in phase II trials: is it useful?
    Freidlin B; Korn EL
    Clin Cancer Res; 2013 Mar; 19(6):1326-34. PubMed ID: 23303215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
    Alosh M; Huque MF; Koch GG
    J Biopharm Stat; 2015; 25(6):1161-78. PubMed ID: 25331097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inference following designs which adjust for imbalances in prognostic factors.
    Barbáchano Y; Coad DS
    Clin Trials; 2013 Aug; 10(4):540-51. PubMed ID: 23832671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting factors predictive of heterogeneity in multivariate event time data.
    Dunson DB; Chen Z
    Biometrics; 2004 Jun; 60(2):352-8. PubMed ID: 15180660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal allocation of participants for the estimation of selection, preference and treatment effects in the two-stage randomised trial design.
    Walter SD; Turner RM; Macaskill P; McCaffery KJ; Irwig L
    Stat Med; 2012 Jun; 31(13):1307-22. PubMed ID: 22362374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.